Cargando…
Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disease without a clear mechanism or drugs for treatment. Therefore, it is crucial to reveal the underlying molecular mechanism and identify potential drugs for PAH. In this study, we first integrated three human lung tissue datas...
Autores principales: | Dong, Haoru, Li, Xiuchun, Cai, Mengsi, Zhang, Chi, Mao, Weiqi, Wang, Ying, Xu, Qian, Chen, Mayun, Wang, Liangxing, Huang, Xiaoying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202883/ https://www.ncbi.nlm.nih.gov/pubmed/34016786 http://dx.doi.org/10.18632/aging.203040 |
Ejemplares similares
-
CCR7 and its related molecules may be potential biomarkers of pulmonary arterial hypertension
por: Cai, Mengsi, et al.
Publicado: (2021) -
Effects of baicalin on collagen Ι and collagen ΙΙΙ expression in pulmonary arteries of rats with hypoxic pulmonary hypertension
por: LIU, PANPAN, et al.
Publicado: (2015) -
Effect of asiaticoside on endothelial cells in hypoxia-induced pulmonary hypertension
por: Wang, Xiaobing, et al.
Publicado: (2018) -
FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19
por: Li, Xiuchun, et al.
Publicado: (2022) -
FGF21 attenuates pulmonary arterial hypertension via downregulation of miR‐130, which targets PPARγ
por: Wang, Meibin, et al.
Publicado: (2022)